Stopping Cancer Before It Starts

Antiva is developing novel topical therapies to treat pre-cancerous cervical lesions as well as the HPV infections that cause these lesions. Currently, there is no treatment for HPV infection; women must wait and see whether their infection clears by itself or progresses to more advanced disease. We are developing a first-in-class therapy that would give women the ability to treat themselves in the privacy of their own homes when their infection is first diagnosed. Our therapy also provides a non-surgical option for women whose disease is more advanced.

Our passionate, experienced team is dedicated to improving health outcomes and access to care worldwide by developing a simple and convenient non-surgical approach to treat HPV and precancerous lesions, supporting the World Health Organization’s global Cervical Cancer Elimination Initiative.

Antiva in the
News

October 19, 2023

Antiva Biosciences Strengthens Leadership with Key New Appointments Read more

May 5, 2023

ANNOUNCEMENT: ASCCP Presents Dr. Tom Cox with Lifetime Achievement Award Read more

April 27, 2023

Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO Read more